FDA Approves First Humira Biosimilar
By Michael Mezher -
Published 23 September 2016
The US Food and Drug Administration (FDA) on Friday announced it had approved Amgen's Amjevita (adalimumab-atto), the first biosimilar version of AbbVie's best-selling biologic Humira (adalimumab).
Categories: News, US, FDA, Biologics and biotechnology, Submission and registration
Tags: Humira, Amjevita, Biosimilar, adalimumab, adalimumab-atto